Nature Biotechnology Podcast

Jeremy Levin is chairman and CEO of Ovid Therapeutics, formerly president and CEO of Teva Pharmaceutical Industries, and former member of the executive committee at Bristol-Myers Squibb, where he led that company's 'string of pearls' strategy. His conversation with Nature Biotechnology covers shifting his mindset from treating patients to business development, his youth in South Africa, and how his past influences his view of the 2016 US presidential election results.

Anu Acharya is founder and CEO of Mapmygenome, a co-founder of Ocimum Biosolutions and a leading light for life science entrepreneurship in India. Her discussion with Nature Biotechnology covers the importance of mentorship, running a consumer genomics company, and grieving the death of a parent.

Anu Acharya is founder and CEO of Mapmygenome, a co-founder of Ocimum Biosolutions and a leading light for life science entrepreneurship in India. Her discussion with Nature Biotechnology covers the importance of mentorship, running a consumer genomics company, and grieving the death of a parent.

Nancy J Kelley, founder and chief executive of Nancy J Kelley + Associates, a consultancy creating and developing projects and institutions for science and medicine, touches on establishing the East River Science Park, excelling at Yale as a young mother of three and why one must take risks in life.

Nancy J Kelley, founder and chief executive of Nancy J Kelley + Associates, a consultancy creating and developing projects and institutions for science and medicine, touches on establishing the East River Science Park, excelling at Yale as a young mother of three and why one must take risks in life.

David Baltimore, president emeritus of the California Institute of Technology, discusses his parents moving him from New York City to Great Neck, Long Island, as a child; his initial interest in animal virology; and getting that Nobel call from Sweden.

David Baltimore, president emeritus of the California Institute of Technology, discusses his parents moving him from New York City to Great Neck, Long Island, as a child; his initial interest in animal virology; and getting that Nobel call from Sweden.

Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotechs and authored a manual nicknamed 'the bible of cloning.' His conversation with Nature Biotechnology covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor.

Tom Maniatis is a founder of Kallyope, and head of the Maniatis lab at Columbia University. Among other things, he's founded several biotechs and authored a manual nicknamed 'the bible of cloning.' His conversation with Nature Biotechnology covers being the first in his family to go to college, the moratorium on recombinant DNA research in Cambridge, Massachusetts, and his long relationship with Jim Watson at Cold Spring Harbor.

Daniel Cohen is chairman and CEO of Pharnext. He was also co-founder of CEPH, Genethon and Millennium, and an early leader in the genomics field. His talk with Nature Biotechnology covers the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra.

Daniel Cohen discusses the industrialization of genomic sequencing, his part in founding Millennium and why the conductor has the most difficult job in an orchestra.

James Wilson is the director of the Gene Therapy Program at the University of Pennsylvania. He is also a founder and chief scientific advisor at Regenx Bio, as well as founder and chairman of scientific advisory council at Dimension Therapeutics. Wilson's conversation covers his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.

Nature Biotechnology talked to Wilson about his love of motocross racing, the triumphs and tribulation of gene therapy (including the Jesse Gelsinger tragedy), and the future of drug pricing.

Bill Rutter is founder, chairman and CEO of Synergenics, which manages a consortium of biotech companies. He was also a founder of Chiron and is credited with bringing the University of California at San Francisco to its prominent position in life sciences research. His discussion with Nature Biotechnology covers building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy.

Nature Biotechnology spoke to Rutter about building out the labs at UCSF, sequencing the hepatitis C virus and his short stint in the Navy.